| Title |
Pharmacoeconomic Outcomes for Pregabalin: A Systematic Review in Neuropathic Pain, Generalized Anxiety Disorder, and Epilepsy from a Spanish Perspective
|
|---|---|
| Published in |
Advances in Therapy, January 2014
|
| DOI | 10.1007/s12325-013-0088-2 |
| Pubmed ID | |
| Authors |
Josep Darbà, Lisette Kaskens, Concepción Pérez, Enrique Álvarez, Ruth Navarro-Artieda, Antoni Sicras-Mainar |
| Abstract |
Pregabalin is an anticonvulsant approved in Europe for the treatment of neuropathic pain, as an adjunct therapy for epileptic seizures, and recently for generalized anxiety disorder. The aim of this study was to conduct a systematic review to evaluate the cost-effectiveness of pregabalin associated with the treatment of its labeled indications from a societal perspective in Spain. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 66 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Master | 6 | 9% |
| Student > Bachelor | 5 | 8% |
| Student > Doctoral Student | 3 | 5% |
| Other | 15 | 23% |
| Unknown | 17 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 23% |
| Psychology | 7 | 11% |
| Neuroscience | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Unspecified | 3 | 5% |
| Other | 10 | 15% |
| Unknown | 22 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2015.
All research outputs
#14,770,397
of 22,738,543 outputs
Outputs from Advances in Therapy
#1,223
of 2,336 outputs
Outputs of similar age
#182,883
of 304,891 outputs
Outputs of similar age from Advances in Therapy
#13
of 18 outputs
Altmetric has tracked 22,738,543 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,336 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,891 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.